ArticleBlood cancer journal2025
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Analytical validation of a modified wild-type blocker qpcr assay for the sensitive DNA-based detection of NPM1 type A in acute myeloid leukemia.Molecular biology reports · 2026Article
- Refined detection of CD34⁺CD38⁻CD45RA⁺ leukemic stem cells using a single-tube flow cytometry assay and its strong association with measurable residual disease in acute myeloid leukemia: a retrospective cohort study.Stem cell research & therapy · 2026Article
- The prognostic value of maintaining minimal residual disease status in patients with acute myeloid leukaemia receiving azacitidine-based therapy.BMC cancer · 2026Article
- Review
- A real-world data study on long-course venetoclax combined with hypomethylating agents in unfit patients.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Carlos Jimenez-VicenteHematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.
Aina CardusInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Sandra Castaño-DiezHematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9044-4665
Guillermo RamilHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.ORCID http://orcid.org/0009-0005-0287-6967
Sara Garcia-AvilaHematology Department. Hospital del Mar, Barcelona, España. Hospital del Mar Research Institute, Barcelona, Spain.
Lucia Gomez-PerezHematology Department. Hospital del Mar, Barcelona, España. Hospital del Mar Research Institute, Barcelona, Spain.
Daniel EstebanHematology Department. ICO-Hospital Universitari Germans Trias i Pujol, Institut de Recerca Josep Carreras. Badalona. Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-8897-3170
Iago ArribasHematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
Antonella Lucia SturlaHematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
Monica Lopez-GuerraInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Alexandra Martinez-RocaHematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2143-5356
Albert Cortes-BullichHematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.
Amanda Isabel Perez-ValenciaHematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.
Ines ZugastiHematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-7666-5055
Ines MongePharmacy Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Esther CarceleroPharmacy Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Ferran Vall-LloveraHospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain.
Susana VivesHematology Department. ICO-Hospital Universitari Germans Trias i Pujol, Institut de Recerca Josep Carreras. Badalona. Universitat Autònoma de Barcelona, Barcelona, Spain.
Jorge SierraHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.
Josep NomdedeuHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.
Guadalupe OñateHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2180-2371
Ana GarridoHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.
Marta PratcoronaHematology Department. Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona and IIB Sant Pau, Barcelona, Spain.
Helena PomaresHematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
Montserrat ArnanHematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
Francesca GuijarroInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0001-6376-0929
Marina Diaz-BeyaHematology Department. Hospital Clínic de Barcelona, Barcelona, Spain.
Jordi EsteveHematology Department. Hospital Clínic de Barcelona, Barcelona, Spain. jesteve@clinic.cat.ORCID http://orcid.org/0000-0002-8056-648X
Spanish CETLAM Group
Funding
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) FIS PI22/01660
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.